NCT06283186 Comparative Exercise-Induced Hypoalgesia in Upper and Lower Limbs: A Randomized Controlled Trial in Healthy Individuals
| NCT ID | NCT06283186 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Centro Universitario La Salle |
| Condition | Healthy Subjects |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2024-04-23 |
| Primary Completion | 2025-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 90 participants in total. It began in 2024-04-23 with a primary completion date of 2025-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized controlled trial with healthy subjects aims to compare exercise-induced hypoalgesia among three groups: one utilizing a lower limb cycle ergometer, another using an upper limb cycle ergometer, and a control group. The exercise protocol involves 30 minutes of aerobic activity at 70-80% of the heart rate reserve. Exercise-induced hypoalgesia will be assessed by measuring pressure pain thresholds in the thigh and elbow. Additionally, a secondary objective is to compare the lower limb and upper limb cycle ergometer groups in terms of their effects on pressure pain thresholds in the thigh and elbow. Thus, the study anticipates observing differences in local and distal hypoalgesia based on the trained region.
Eligibility Criteria
Inclusion Criteria: * Asymptomatic subjects aged between 18 and 64 years. Exclusion Criteria: * Cardiovascular, respiratory, metabolic, neurological, or osteomuscular signs or pathologies. * History of epilepsy. * Pregnant * Pharmacological treatment. * Participants who present any type of pain on the day of the measurements or who have frequently suffered pain during the previous 12 weeks.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06283186 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 64 Years, studying Healthy Subjects. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06283186 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06283186 currently recruiting?
Yes, NCT06283186 is actively recruiting participants. Contact the research team at alvaro.reina@lasallecampus.es for enrollment information.
Where is the NCT06283186 trial being conducted?
This trial is being conducted at Madrid, Spain.
Who is sponsoring the NCT06283186 clinical trial?
NCT06283186 is sponsored by Centro Universitario La Salle. The trial plans to enroll 90 participants.